High-dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease

Rübo, J.; Albrecht, Klaus; Lasch, Peter; Laufkötter, E; Leititis, J. U.; Marsan, Daruk; Niemeyer, Birgit; Roesler, Jochen; Roll, Claudia; Roth, B.; Stockhausen, H. B. von; Widemann, Brigitte C.; Wahn, V.

doi:10.1016/s0022-3476(05)82551-x

Cited by 106 publications

(80 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two of 16 patients receiving IVIG required exchange transfusion compared to 11 of 16 controls (transfusion rate 12.5 vs. 69%). Mean serum bilirubin levels were lower in treated patients despite the less frequent exchange transfusion implying decreased hemolysis [3] . In another study, the requirement for transfusions (exchange transfusion and/or simple blood transfusion) was reduced from 66 to 42% and treated infants required fewer days of hospitalization [4] .…”

Section: Mechanism Of Actionmentioning

confidence: 87%

“…Many studies have shown a beneficial effect of postnatal IVIG therapy in the management of neonates with RhD alloimmunization [3][4][5][6] . The mechanism proposed is blockade of Fc receptors and hemolysis [7] .…”

Section: Mechanism Of Actionmentioning

confidence: 99%

“…The mechanism proposed is blockade of Fc receptors and hemolysis [7] . In 1992, Rubo et al [3] demonstrated in a randomized control non-blinded multicenter trial that immunoglobulins given to the Rh-sensitized neonates reduced the need for exchange transfusions. Two of 16 patients receiving IVIG required exchange transfusion compared to 11 of 16 controls (transfusion rate 12.5 vs. 69%).…”

Section: Mechanism Of Actionmentioning

confidence: 99%

See 2 more Smart Citations

Fetal Intravenous Immunoglobulin Therapy in Rhesus Hemolytic Disease

Kriplani¹,

Singh²,

Mandal³

2006

Gynecol Obstet Invest

View full text Add to dashboard Cite

Intrauterine blood transfusion is the mainstay of treatment of fetal rhesus hemolytic anemia with optimal perinatal outcome. Postnatal immunoglobulin therapy has been successfully used in the management of alloimmunized neonates and has shown to decrease the need for exchange transfusion. We report the first case series of fetal immunoglobulin therapy in the antenatal management of severe Rh incompatibility.

show abstract

Section: Mechanism Of Actionmentioning

confidence: 87%

Section: Mechanism Of Actionmentioning

confidence: 99%

Section: Mechanism Of Actionmentioning

confidence: 99%

See 1 more Smart Citation

Fetal Intravenous Immunoglobulin Therapy in Rhesus Hemolytic Disease

Kriplani¹,

Singh²,

Mandal³

2006

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…Intravenous immune globulin reduces jaundice in many cases of neonatal isoimmunization [41,42]. The mechanism of intravenous immune globulin is probably similar to that found in neonatal isoimmune thrombocytopenia, such as the blockade of immunoglobulin constant fragment receptors and the resultant inhibition of hemolysis of antibody-coated erythrocytes.…”

Section: Types Of Treatmentmentioning

confidence: 72%

Prevention of Bilirubin Encephalopathy

Bertini

Dani²,

Pezzati³

et al. 2001

Neonatology

View full text Add to dashboard Cite

Prevention of bilirubin encephalopathy is based on the detection of infants at risk of developing a significant hyperbilirubinemia. This task can be accomplished by performing a simple umbilical cord blood test, such as blood group, Rh, Coombs’ test and glucose-6-phosphate dehydrogenase, in order to detect hemolytic diseases. In preterm infants, the prevention of hyperbilirubinemia with phototherapy is a relatively simple task, since these infants are cared for in hospital. Early hospital discharge of full-term neonates represents a major concern. The management of neonatal jaundice requires that therapy begins when total serum bilirubin levels are significantly below the levels at which kernicterus is considered an immediate threat. Unfortunately, determination of serum bilirubin is a painful procedure, and is not very accurate since there is a high variability in laboratory measurements. The accuracy and precision of a new transcutaneous bilirubin measurement, comparable to the standard of care laboratory test, makes the daily evaluation of transcutaneous bilirubin measurement a useful tool in distinguishing physiological from nonphysiological hyperbilirubinemia, and determining the bilirubin increment in the first days of life. Full-term neonates who lose a significant amount of weight are especially at risk of significant hyperbilirubinemia and must be treated with ad libitum feeding and intensive phototherapy.

show abstract

“…47 Use of IVIG can be considered in hyperbilirubinemic newborns with a positive DAT and evidence of hemolysis. In some cases, use of IVIG can be considered in the presence of ABO blood group incompatibility (mother blood group O, baby A or B) but negative DAT, provided the jaundice is behaving as if it were of hemolytic nature (see Table 2).…”

Section: Use Of Intravenous Immune Globulinmentioning

confidence: 99%